SG Americas Securities LLC Grows Position in Kymera Therapeutics, Inc. $KYMR

SG Americas Securities LLC boosted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 169.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,693 shares of the company’s stock after buying an additional 14,261 shares during the period. SG Americas Securities LLC’s holdings in Kymera Therapeutics were worth $1,766,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Holocene Advisors LP purchased a new position in shares of Kymera Therapeutics during the third quarter worth approximately $47,563,000. Commodore Capital LP purchased a new stake in Kymera Therapeutics in the 2nd quarter valued at $32,730,000. Alyeska Investment Group L.P. boosted its stake in Kymera Therapeutics by 1,130.2% during the 3rd quarter. Alyeska Investment Group L.P. now owns 615,091 shares of the company’s stock worth $34,814,000 after purchasing an additional 565,091 shares during the period. Federated Hermes Inc. acquired a new stake in Kymera Therapeutics during the 3rd quarter worth $31,622,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Kymera Therapeutics by 121.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after purchasing an additional 491,737 shares during the last quarter.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $85.40 on Monday. The firm has a market cap of $6.97 billion, a price-to-earnings ratio of -23.21 and a beta of 2.28. Kymera Therapeutics, Inc. has a 52-week low of $19.44 and a 52-week high of $103.00. The company’s 50-day simple moving average is $81.57 and its 200-day simple moving average is $72.33.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The firm had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. During the same quarter in the previous year, the business earned ($0.88) EPS. Kymera Therapeutics’s revenue for the quarter was down 60.8% on a year-over-year basis. Equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insiders Place Their Bets

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 4,895 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $85.30, for a total value of $417,543.50. Following the completion of the transaction, the chief financial officer owned 232,588 shares in the company, valued at approximately $19,839,756.40. This represents a 2.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jeremy G. Chadwick sold 14,640 shares of the firm’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $85.46, for a total value of $1,251,134.40. Following the completion of the sale, the chief operating officer directly owned 61,202 shares of the company’s stock, valued at approximately $5,230,322.92. This trade represents a 19.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 316,778 shares of company stock valued at $26,728,572 over the last 90 days. 16.01% of the stock is owned by corporate insiders.

Key Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Multiple research firms have raised price targets and reiterated buy/outperform views (Mizuho, Oppenheimer, B. Riley, Leerink, UBS), supporting upside expectations for KYMR. Analyst Upgrades and Targets
• Positive Sentiment: Large institutional holders (Baker Bros., Avoro, Vanguard, Price T. Rowe, BVF) increased positions in recent quarters, signaling continued fund-level conviction in Kymera’s Pegasus degrader platform and pipeline. Institutional Activity
• Neutral Sentiment: Company fundamentals/context: Kymera is a clinical‑stage degrader-focused biotech with a mixed near‑term financial picture (recent quarter missed revenue and EPS estimates). These operational results remain a material background factor for how investors value upcoming clinical and partnership milestones. Earnings and Company Profile
• Negative Sentiment: Director Elena Ridloff sold 4,600 shares on April 1 at an average price of ~$85.42 (disclosed via SEC). Large director sales can create near-term selling pressure or signal personal liquidity needs. Ridloff sale (AmericanBankingNews)
• Negative Sentiment: Additional disclosures show Ridloff sold 7,400 shares on March 31 and the April 1 sale was also filed with the SEC. Total recent Ridloff sales amount to ~12,000 shares across the two trades. Ridloff SEC filing
• Negative Sentiment: COO Jeremy G. Chadwick disclosed multiple sales (7,600 on March 31 and 14,640 on April 1) totaling ~22,240 shares at ~\$85.4 average — a roughly double‑digit percentage reduction in his reported ownership. Senior‑exec selling of this size can weigh on sentiment. Chadwick SEC filing
• Negative Sentiment: Multiple independent reports aggregated these insider trades (InsiderTrades, MarketBeat), increasing transparency but also spotlighting the concentration of recent insider liquidity. InsiderTrades summary

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Thursday, January 22nd. Citigroup boosted their price target on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Bank of America upped their price objective on Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. BTIG Research lowered their target price on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Finally, Truist Financial boosted their target price on Kymera Therapeutics from $80.00 to $116.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and an average target price of $118.90.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.